Background/Purpose: The Biologic Treatment Registry Across Canada (BioTRAC) was a prospective, observational registry that enrolled psoriatic arthritis (PsA) patients treated with subcutaneous golimumab (GLM) between 2010 and 2017.

Methods: Patient visits occurred at baseline and every 6 months thereafter. Multivariate logistic regression was used to identify independent predictors of achieving specific efficacy and safety endpoints and included the following covariates: age, gender, disease duration, enrolment period, concomitant medication, smoking and employment.

Results: A total of 281 patients were enrolled and followed for a mean duration of 1.9 years. The proportion of male gender was 46.3% and the mean disease duration at baseline was 6.1 years.

MDA was more likely to be achieved with lower baseline DAS28-CRP [OR (95% CI): 0.62 (0.45–0.84); p=0.002] and in patients who were employed [2.64 (1.22–5.71); p=0.014]. VLDA was more likely to be achieved with lower age [OR (95% CI): 0.96 (0.94–0.99); p=0.005], lower baseline DAS28-CRP [0.63 (0.44–0.89); p=0.009] and in patients who were employed [6.45 (2.30–18.27); p< 0.001], whereas VLDA was less likely to be achieved in patients who smoked [0.30 (0.10–0.92); p=0.035].

DAPSA LDA was more likely to be achieved with lower baseline DAPSA [OR (95% CI): 0.96 (0.94–0.98); p< 0.001]. DAPSA remission was more likely to be achieved with lower age [OR (95% CI): 0.98 (0.95–1.00); p=0.048] and lower baseline DAPSA [0.98 (0.96–1.00); p=0.043], while less likely to be achieved with later enrolment [2016-2017 vs. 2010–2012: 0.30 (0.11–0.78); p=0.014] and in patients who smoked [0.37 (0.15–0.93); p=0.035]. HAQ < 0.5 was more likely to be achieved in male vs. female gender [OR (95%): 2.03 (1.08–3.83); p=0.028] and in patients with lower baseline HAQ scores [0.19 (0.11–0.34); p< 0.001].

AEs were more likely to occur with baseline concomitant DMARD [1.97 (1.07–3.63); p=0.030] or NSAID use [1.88 (1.05–3.37); p=0.033], yet less likely in male vs. female [0.54 (0.30–0.98); p=0.043]. SAEs were more likely to occur with older age [1.04 (1.00–1.07); p=0.041], and less likely in patients enrolled later [2013–2015 vs. 2010–2012: 0.05 (0.01–0.18); p< 0.001 and 2016–2017 vs. 2010–2012: 0.03 (0.01–0.14); p< 0.001]. Being employed at baseline was a significant positive predictor of GLM retention [0.61 (0.38–0.97); p=0.035].

Conclusion: In PsA patients treated with golimumab, young age, employment and lower disease activity at baseline were associated with better treatment outcomes.

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/predictors-of-response-adverse-events-and-treatment-retention-in-psoriatic-arthritis-patients-treated-with-golimumab-in-a-prospective-observational-registry/